NASDAQ
05.12.25 | 22:00
1,420 US-Dollar
+3,65 % +0,050
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 13.11. | Jefferies initiates coverage on ALX Oncology stock with Buy rating | 4 | Investing.com | ||
| 07.11. | ALX Oncology anticipates $2B-$4B HER2/CD47 breast cancer market opportunity while advancing biomarker-driven strategies | 6 | Seeking Alpha | ||
| 07.11. | ALX ONCOLOGY HOLDINGS INC - 10-Q, Quarterly Report | - | SEC Filings | ||
| 07.11. | Earnings Call Transkript: ALX Oncology zeigt vielversprechende Fortschritte bei Medikamentenentwicklung in Q3 2025 | 2 | Investing.com Deutsch | ||
| ALX ONCOLOGY Aktie jetzt für 0€ handeln | |||||
| 07.11. | ALX Oncology GAAP EPS of -$0.41 misses by $0.04 | 3 | Seeking Alpha | ||
| 07.11. | ALX Oncology Reports Third Quarter 2025 Financial Results and Provides Corporate Update | 170 | GlobeNewswire (Europe) | ASPEN-06 data to be presented at SITC demonstrates that evorpacept drove durable clinical benefit across all efficacy measures in HER2+ gastric cancer patients with high CD47 expression Phase 2 ASPEN-09-Breast... ► Artikel lesen | |
| 07.11. | ALX ONCOLOGY HOLDINGS INC - 8-K, Current Report | - | SEC Filings | ||
| 06.11. | Examining the Future: ALX Oncology Holdings' Earnings Outlook | 2 | Benzinga.com | ||
| 23.10. | Alx Oncology stock jumps after presenting preclinical ADC data at conference | 3 | Investing.com | ||
| 23.10. | Präklinische ADC-Daten beflügeln Aktie von Alx Oncology | 1 | Investing.com Deutsch | ||
| 23.10. | ALX Oncology stellt präklinische Daten für neuartigen EGFR-Krebswirkstoff vor | 7 | Investing.com Deutsch | ||
| 23.10. | ALX Oncology presents preclinical data for novel EGFR cancer drug | 1 | Investing.com | ||
| 03.10. | ALX Oncology to present CD47 biomarker data for evorpacept at SITC | 1 | Investing.com | ||
| 03.10. | ALX Oncology to Present Updated Data from Phase 2 ASPEN-06 Trial, Highlighting CD47 Expression as a Predictive Biomarker in HER2+ Gastric Cancer, at 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting | 3 | GlobeNewswire (USA) | ||
| 12.09. | ALX Oncology appoints board member Klencke as interim CMO | 2 | Investing.com | ||
| 12.09. | ALX Oncology CMO Alan Sandler Resigns; Appoints Board Member Barbara Klencke As Interim CMO | 1 | RTTNews | ||
| 12.09. | ALX Oncology Appoints Board Member Barbara Klencke, M.D., as Interim Chief Medical Officer | 259 | GlobeNewswire (Europe) | Dr. Barbara Klencke is an accomplished clinical leader with a distinguished track record in oncology drug development who currently serves on the Company's Board of Directors and will step down from... ► Artikel lesen | |
| 12.09. | ALX ONCOLOGY HOLDINGS INC - 8-K, Current Report | 1 | SEC Filings | ||
| 19.08. | ALX Oncology doses first patient in phase 1 trial of EGFR cancer drug | 1 | Investing.com | ||
| 12.08. | ALX Oncology Q2 2025 slides: biomarker strategy shows promise as cash runway extends | 6 | Investing.com |
1 2 Weiter >>
33 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 5,454 | -2,57 % | DAX-Check LIVE: Aurubis, Evotec, Formycon, Infineon, Porsche SE, Siemens Energy im Fokus | Die Erholung an der Börse hat sich zur Wochenmitte nicht fortgesetzt. Der DAX startete zwar mit kleinen Gewinnen in den Tag, rutschte im Verlauf jedoch ins Minus und schloss schließlich bei 23.694 Punkten... ► Artikel lesen | |
| MODERNA | 23,785 | 0,00 % | Moderna, Lonza, NurExone: Wie Biotech-Akteure den Weg in neue Wachstumsfelder ebnen | ||
| NOVAVAX | 5,875 | -0,93 % | Novavax, Inc. (NVAX): A Bull Case Theory | ||
| CRISPR THERAPEUTICS | 49,200 | 0,00 % | Crispr Therapeutics pares loss amid takeover speculation | ||
| INOVIO PHARMACEUTICALS | 1,790 | 0,00 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports Third Quarter 2025 Financial Results and Recent Business Highlights | Completed rolling Biologics License Application (BLA) submission seeking accelerated approval for lead candidate INO-3107; requested priority review
Expect... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 8,110 | -1,58 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| DEFENCE THERAPEUTICS | 0,550 | +0,36 % | Defence Therapeutics gibt die Einrichtung eines Scientific Advisory Board bekannt, um die Weiterentwicklung der Accum-verstärkten Antikörper-Wirkstoff-Konjugat-Programme zu unterstützen | Montreal, QC, Kanada, 4. Dezember 2025 / IRW-Press / Defence Therapeutics Inc. ("Defence" oder das "Unternehmen"), ein Biotechnologieunternehmen, das
eine proprietäre intrazelluläre Verabreichungsplattform... ► Artikel lesen | |
| EDITAS MEDICINE | 2,120 | +2,66 % | Editas Medicine, Inc.: Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate | EDIT-401 achieved ~90% mean LDL-C reduction with single dose in non-human primates EDIT-401 on track for human proof-of-concept data by end of 2026 Strong cash position with operational runway into... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 19,000 | -0,63 % | Aktien New York: Anleger realisieren Gewinne nach Rekordlauf | NEW YORK (dpa-AFX) - Nach ihrem jüngsten Rekordkurs haben die Anleger an den US-Aktienmärkten am Dienstag Druck aus dem Kessel gelassen. Die Investoren hinterfragten zunehmend die hohen Bewertungen... ► Artikel lesen | |
| BIOMARIN PHARMACEUTICAL | 46,140 | +0,61 % | SYM vs. BMRN: Which Technology Services Stock Has an Edge Right Now? | ||
| EXELIXIS | 38,230 | +0,37 % | Adagene Inc.: Adagene Expands SAFEbody Collaboration and License Agreement with Exelixis to Develop Third Novel Masked Antibody-Drug Conjugate | SAN DIEGO and SUZHOU, China, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene") (Nasdaq: ADAG) today announced an amendment to the 2021 collaboration and license agreement with Exelixis.... ► Artikel lesen | |
| PACIFIC BIOSCIENCES OF CALIFORNIA | 2,021 | -1,77 % | PacBio Announces Third Quarter 2025 Financial Results | MENLO PARK, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended September 30, 2025. Third quarter results: Q3 2025Q3 2024Revenue$38.4... ► Artikel lesen | |
| HALOZYME THERAPEUTICS | 55,04 | +1,18 % | Merck's Keytruda SC launch in Germany faces new hurdle as Halozyme scores preliminary injunction | ||
| NEUROCRINE BIOSCIENCES | 135,05 | +1,12 % | Neurocrine Bio. stock price target raised to $200 from $175 at TD Cowen | ||
| VAXART | 0,282 | 0,00 % | Vaxart, Inc.: Vaxart Provides Business Update and Reports Third Quarter 2025 Financial Results | Entered into an exclusive license agreement with Dynavax for the Company's COVID-19 oral pill vaccine candidate for potential cumulative proceeds of up to $700 million plus royalties Completed enrollment... ► Artikel lesen |
Das Unternehmen ALX ONCOLOGY HOLDINGS INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,050 (+3,65 %) liegt der Kurs bei 1,420 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ALX ONCOLOGY HOLDINGS INC finden Sie auf Wallstreet Online.